Kodiak Sciences (KOD) Stock Forecast, Price Target & Predictions
KOD Stock Forecast
Kodiak Sciences stock forecast is as follows: an average price target of $11.00 (represents a 62.96% upside from KOD’s last price of $6.75) and a rating consensus of 'Buy', based on 9 wall street analysts offering a 1-year stock forecast.
KOD Price Target
The average price target for Kodiak Sciences (KOD) is $11.00 based on 1-year price targets from 9 Wall Street analysts in the past 3 months, with a price target range of $20.00 to $2.00. This represents a potential 62.96% upside from KOD's last price of $6.75.
KOD Analyst Ratings
According to 9 Wall Street analysts, Kodiak Sciences's rating consensus is 'Buy'. The analyst rating breakdown for KOD stock is 0 'Strong Buy' (0.00%), 4 'Buy' (44.44%), 3 'Hold' (33.33%), 2 'Sell' (22.22%), and 0 'Strong Sell' (0.00%).
Kodiak Sciences Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Dec 09, 2024 | Michael Yee | Jefferies | $20.00 | $11.48 | 74.22% | 196.30% |
| Sep 24, 2024 | Andrea Tan | Goldman Sachs | $2.00 | $2.43 | -17.78% | -70.37% |
| Nov 14, 2022 | Morgan Stanley | $9.00 | $7.59 | 18.58% | 33.33% | |
| Nov 10, 2022 | Goldman Sachs | $8.00 | $7.22 | 10.80% | 18.52% | |
| Aug 15, 2022 | Morgan Stanley | $12.00 | $11.73 | 2.30% | 77.78% | |
| Aug 10, 2022 | Chardan Capital | $18.00 | $11.84 | 52.03% | 166.67% | |
| Aug 09, 2022 | Truist Financial | $15.00 | $11.13 | 34.77% | 122.22% | |
| Aug 09, 2022 | Goldman Sachs | $9.00 | $11.55 | -22.08% | 33.33% | |
| May 24, 2022 | Goldman Sachs | $5.00 | $6.55 | -23.66% | -25.93% | |
| May 11, 2022 | Goldman Sachs | $7.00 | $5.20 | 34.62% | 3.70% | |
| Feb 11, 2022 | Andrea Tan | Goldman Sachs | $70.00 | $56.79 | 23.26% | 937.04% |
| Nov 12, 2021 | Matthew Luchini | BMO Capital | $114.00 | $112.33 | 1.49% | 1588.89% |
The latest Kodiak Sciences stock forecast, released on Dec 09, 2024 by Michael Yee from Jefferies, set a price target of $20.00, which represents a 74.22% increase from the stock price at the time of the forecast ($11.48), and a 196.30% increase from KOD last price ($6.75).
Kodiak Sciences Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 1 | 2 |
| Avg Price Target | - | $20.00 | $11.00 |
| Last Closing Price | $6.75 | $6.75 | $6.75 |
| Upside/Downside | -100.00% | 196.30% | 62.96% |
In the current month, the average price target of Kodiak Sciences stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Kodiak Sciences's last price of $6.75. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Sep 24, 2024 | Goldman Sachs | Sell | Sell | Hold |
| Sep 05, 2024 | H.C. Wainwright | Neutral | Initialise | |
| Apr 04, 2024 | UBS | Neutral | Neutral | Hold |
| Apr 01, 2024 | Barclays | Underweight | Underweight | Hold |
| Jul 24, 2023 | Raymond James | Outperform | Initialise | |
| Jul 24, 2023 | Citigroup | Neutral | Overweight | Initialise |
| Jul 24, 2023 | RBC Capital | Outperform | Initialise | |
| Jul 24, 2023 | Barclays | Equal-Weight | Initialise | |
| Jul 24, 2023 | Goldman Sachs | Neutral | Buy | Initialise |
| Nov 14, 2022 | Morgan Stanley | Equal-Weight | Equal-Weight | Hold |
| Aug 15, 2022 | Morgan Stanley | Equal-Weight | Equal-Weight | Hold |
| Aug 10, 2022 | Chardan Capital | Buy | Buy | Hold |
| Aug 09, 2022 | Goldman Sachs | Neutral | Neutral | Hold |
| May 17, 2022 | Morgan Stanley | Equal-Weight | Equal-Weight | Hold |
| May 11, 2022 | Goldman Sachs | Neutral | Neutral | Hold |
| Feb 24, 2022 | Morgan Stanley | Equal-Weight | Equal-Weight | Hold |
| Feb 24, 2022 | Citigroup | Neutral | Neutral | Hold |
Kodiak Sciences's last stock rating was published by Goldman Sachs on Sep 24, 2024. The company gave KOD a "Sell" rating, the same as its previous rate.
Kodiak Sciences Financial Forecast
Kodiak Sciences Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 20 | Mar 19 | |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - | $408.04K | $10.57K |
| High Forecast | - | - | - | - | - | - | - | $489.64K | $12.68K |
| Low Forecast | - | - | - | - | - | - | - | $326.43K | $8.46K |
| # Analysts | - | - | - | - | - | - | - | 16 | 14 |
| Surprise % | - | - | - | - | - | - | - | - | - |
Kodiak Sciences's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. KOD's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
Kodiak Sciences EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 20 | Mar 19 | |
|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | 16 | 14 |
| EBITDA | - | - | - | - | - | - | - | $-24.17M | $-7.85M |
| Avg Forecast | - | - | - | - | - | - | - | $-21.07M | $-10.74M |
| High Forecast | - | - | - | - | - | - | - | $-16.86M | $-8.59M |
| Low Forecast | - | - | - | - | - | - | - | $-25.28M | $-12.89M |
| Surprise % | - | - | - | - | - | - | - | 1.15% | 0.73% |
undefined analysts predict KOD's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Kodiak Sciences's previous annual EBITDA (undefined) of $NaN.
Kodiak Sciences Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 20 | Mar 19 | |
|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | 16 | 14 |
| Net Income | - | - | - | - | - | - | - | $-24.39M | $-7.98M |
| Avg Forecast | $-49.99M | $-58.14M | $-61.03M | $-55.25M | $-46.48M | $-47.60M | $-45.80M | $-20.15M | $-10.29M |
| High Forecast | $-49.99M | $-58.14M | $-61.03M | $-51.20M | $-41.67M | $-47.60M | $-45.80M | $-16.12M | $-8.23M |
| Low Forecast | $-49.99M | $-58.14M | $-61.03M | $-59.29M | $-51.29M | $-47.60M | $-45.80M | $-24.18M | $-12.35M |
| Surprise % | - | - | - | - | - | - | - | 1.21% | 0.78% |
Kodiak Sciences's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. KOD's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Kodiak Sciences SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 20 | Mar 19 | |
|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | 16 | 14 |
| SG&A | - | - | - | - | - | - | - | $5.55M | $2.74M |
| Avg Forecast | - | - | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - | - | - |
Kodiak Sciences's average Quarter SG&A projection for Jun 24 is -, based on 0 Wall Street analysts, with a range of - to -. The forecast indicates a -100.00% fall compared to KOD last annual SG&A of $5.55M (Mar 20).
Kodiak Sciences EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 20 | Mar 19 | |
|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | 16 | 14 |
| EPS | - | - | - | - | - | - | - | $-0.54 | $-0.21 |
| Avg Forecast | $-0.95 | $-1.10 | $-1.16 | $-1.05 | $-0.88 | $-0.90 | $-0.87 | $-0.47 | $-0.37 |
| High Forecast | $-0.95 | $-1.10 | $-1.16 | $-0.97 | $-0.79 | $-0.90 | $-0.87 | $-0.47 | $-0.37 |
| Low Forecast | $-0.95 | $-1.10 | $-1.16 | $-1.13 | $-0.97 | $-0.90 | $-0.87 | $-0.47 | $-0.37 |
| Surprise % | - | - | - | - | - | - | - | 1.16% | 0.57% |
According to undefined Wall Street analysts, Kodiak Sciences's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to KOD previous annual EPS of $NaN (undefined).
Kodiak Sciences Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| SPRO | Spero Therapeutics | $0.86 | $10.00 | 1062.79% | Buy |
| CKPT | Checkpoint Therapeutics | $2.84 | $20.00 | 604.23% | Buy |
| TIL | Instil Bio | $26.31 | $150.00 | 470.13% | Hold |
| RVPH | Reviva Pharmaceuticals | $1.79 | $10.00 | 458.66% | Buy |
| BMEA | Biomea Fusion | $4.22 | $23.33 | 452.84% | Buy |
| CTMX | CytomX Therapeutics | $0.82 | $3.47 | 323.17% | Buy |
| GOSS | Gossamer Bio | $0.92 | $3.75 | 307.61% | Buy |
| ASMB | Assembly Biosciences | $13.86 | $35.50 | 156.13% | Buy |
| STOK | Stoke Therapeutics | $10.51 | $26.50 | 152.14% | Buy |
| KOD | Kodiak Sciences | $6.75 | $11.00 | 62.96% | Buy |
| SRPT | Sarepta Therapeutics | $115.45 | $184.00 | 59.38% | Buy |
| MDGL | Madrigal Pharmaceuticals | $326.33 | $315.75 | -3.24% | Buy |
| AKRO | Akero Therapeutics | $54.00 | $50.00 | -7.41% | Buy |